Consistent with this idea, Velez et al. found that an EZH2 PROTAC degrader induces enhanced EZH2 degradation and has stronger antiproliferative effects than other methods to target EZH2 in AML cells.97 The gene discussed is EZH2; the disease is acute myeloid leukemia.